6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These findings have informed clinical practice guidelines and policy, which now recommend that SMBG not be used routinely in this group (21–26).”
In the citing paper
“While the drug manufacturer is currently offering a savings card program for some patients for whom pricing is a barrier, payor coverage for tirzepatide will likely be a barrier to patient use, especially before tirzepatide has been officially recognized as a standard of care in professional guidelines. 2”
From Tirzepatide: Clinical review of the twincretin injectable (2023) · cites this paper as [2]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“33% with metformin as initial pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (33).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Research works printed but not linked: 1
- Dicembrini, Impact of technology on glycemic control in type 2 diabetes: a meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion, Diabetes Obes Metab
Cited by
Items 301–400 of 846
Campbell, P. T., Newton, C. C., Jacobs, E. J., McCullough, M. L., Wang, Y., Rees‐Punia, E., Guinter, M. A., Murphy, N., Koshiol, J. E., Dehal, A. N., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0082 · Cited by 15
Salinero-Fort, M. Á., Andrés-Rebollo, F. J. S., Cárdenas‐Valladolid, J., Mostaza, J. M., Lahoz, C., Rodríguez‐Artalejo, F., Gómez‐Campelo, P., Vich-Pérez, P., Jiménez‐García, R., López‐de‐Andrés, A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271632 · Cited by 9
Kidie, A. A., Ayal, B. G., Ayele, T., Fentie, E. A., & Lakew, A. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-19909-8 · Cited by 14
Bawazeer, N. M., Alshehri, L. H., Alharbi, N. M., Alhazmi, N. A., Alrubaysh, A. F., Alkasser, A. R., & Aburisheh, K. H. (2022) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2022-000553 · Cited by 11
Leow, Y., Chan, W., Goh, G. B., Wong, V. W., Fan, J., Kim, Y. S., Kim, S. U., Nakajima, A., Seto, W., Lee, I., et al. (2023) · Journal of Viral Hepatitis · doi:10.1111/jvh.13796 · Cited by 11
Ferreira, M. A., Neves, J. S., Neves, C., & Carvalho, D. M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02070-7 · Cited by 15
He, J., Song, C., Wang, H., Zhang, R., Yuan, S., & Dou, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110693 · Cited by 10
Relationship between inflammatory markers and coronary slow flow in type 2 diabetic patients
Elsanan, M., Tahoon, I. H. H. H., Mohamed, G. I., ZeinElabdeen, S. G., & Shehata, I. E. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03275-y · Cited by 14
Perez-Belmonte, L. M., Ricci, M., Sanz‐Cánovas, J., Millán‐Gómez, M., Osuna‐Sánchez, J., Ruiz-Moreno, M. I., Bernal-López, M. R., Lopez-Carmona, M. D., Jiménez-Navarro, M. F., Gómez‐Doblas, J. J., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163540 · Cited by 12
Wilmot, E. G., Close, K. L., Jurišić‐Eržen, D., Bruttomesso, D., Ampudia‐Blasco, F. J., Bosnyák, Z., de Climens, A. R., Bigot, G., Peters, A. L., Renard, É., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14416 · Cited by 14
Gómez, P. R. D. V., Piñar-Gutiérrez, A., Guerrero-Vázquez, R., Bellido, V., Morales, C., Sancho-Márquez, M. P., Espejo-García, P., Gros‐Herguido, N., López-Gallardo, G., Martínez‐Brocca, M. A., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4508633 · Cited by 12
“Prioritising the prevention of severe hypoglycaemias and hyperglycaemias with associated life-threatening conditions or the need for hospital admission is considered to be one of the fundamental therapeutic goals [43].”
BackgroundFrei, T., Chang, C.-H., Filo, M., Arampatzis, A., & Khammash, M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.06.412304 · Cited by 10
Longitudinal Studies of Wearables in Patients with Diabetes: Key Issues and Solutions
Alhaddad, A. Y., Aly, H., Gad, H., Elgassim, E., Mohammed, I., Baagar, K. A. M., Al-Ali, A. K., Sadasivuni, K. K., Cabibihan, J., & Malik, R. A. (2023) · Sensors · doi:10.3390/s23115003 · Cited by 16
Constrained Versus Unconstrained Model Predictive Control for Artificial Pancreas
Toffanin, C., & Magni, L. (2023) · IEEE Transactions on Control Systems Technology · doi:10.1109/tcst.2023.3291564 · Cited by 11
Time Perspective, Dietary Behavior, and Glycemic Control in Patients With Type 2 Diabetes
Jin, P., Wang, X., Li, A., Dong, H., & Ji, M. (2023) · Nursing Research · doi:10.1097/nnr.0000000000000689 · Cited by 9
“Glycemic Control Measuring HbA1c is the gold standard in evaluating patients ’ control of diabetes, and an HbA1c value of less than 7% indicates optimal glycemic control (American Diabetes Association, 2021).”
BackgroundInfluentialde Frel, D. L., Schroijen, M. A., Aardoom, J. J., van Gils, W., Huisman, S. D., Janssen, V. R., Versluis, A., Kleinsmann, M. S., Atsma, D. E., & Pijl, H. (2024) · JMIR Human Factors · doi:10.2196/45055 · Cited by 8
“Inadequate glycemic regulation increases the risk of diabetes-related complications and mortality, and it increases medication use and health care costs [10,11].”
BackgroundWarren, M., Bergenstal, R. M., Hager, M., Bashan, E., & Hodish, I. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0041 · Cited by 11
“Descriptions and validations of the technology as a standard of care for glycemic management and hypoglycemia prevention in patients with type 2 diabetes can be found elsewhere, 14 including data on long-term adherence.”
Guo, H., Han, F., Qu, J.-R., Pan, C., Sun, B., & Chen, L. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2413920 · Cited by 12
“…keeping hba1c at a reasonable level can tremendously reduce the risk of DR. according to the 2019 american Diabetes association (aDa) guidelines [45], the hba1c level of diabetic patients should be controlled below 6.5%, and those with higher hba1c levels are more susceptible to complications.…”
BackgroundInfluentialDietary Diversity as a Risk Factor for Obesity in Algerian Patients with Type 2 Diabetes Mellitus
Bounihi, A., Saidi, H., Bouazza, A., Benbaibeche, H., Azzouz, M., & Koceir, E.-A. (2021) · Healthcare · doi:10.3390/healthcare9091229 · Cited by 11
Cichoń, E., Kiejna, A., Gondek, T. M., Obrębski, M., Sutkowska, E., Lloyd, C. E., Sartorius, N., & Kokoszka, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s322850 · Cited by 10
Reid, L. A., Zheng, S., Mendoza, J. A., Reboussin, B. A., Roberts, A. J. C., Sauder, K. A., Lawrence, J. M., Jensen, E. T., Henkin, L. F., Flory, K., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1807 · Cited by 9
Chan, C. Y., Hoi, B. P.-K., & Wong, E. L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.957754 · Cited by 9
Soares, A. R., Coelho, M., Tracey, M., Carvalho, D. M., & Silva‐Nunes, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01358-1 · Cited by 11
Kirby, N. V., Meade, R. D., Poirier, M. P., Sigal, R. J., Boulay, P., & Kenny, G. P. (2023) · Experimental Physiology · doi:10.1113/ep090915 · Cited by 8
Glycemic control level alters working memory neural dynamics in adults with type 2 diabetes
Embury, C. M., Lord, G. H., Drincic, A., Desouza, C. V., & Wilson, T. W. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad119 · Cited by 11
Lee, E., Yun, J., Cha, S., Lim, S., Lee, J., Ahn, Y., Yoon, K., & Ko, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105300 · Cited by 11
Examining Liver Function in Adults with Diabetes in the United States
Sakharkar, P., & Deb, S. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31851 · Cited by 9
Wooldridge, J. S., Soriano, E. C., Harris, D. E., & Afari, N. (2021) · Diabetes Spectrum · doi:10.2337/ds21-0020 · Cited by 10
Łukasiewicz, A., Kiejna, A., Cichoń, E., Jodko-Modlińska, A., Obrębski, M., & Kokoszka, A. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s320909 · Cited by 11
Algeffari, M., Hussain, S., AlMogbel, T. A., Alsharidah, M. S., Alghadouni, H. A., & Mahmood, F. M. (2022) · Diabetes Care · doi:10.2337/dc21-1655 · Cited by 10
Eichenlaub, M., Pleus, S., Shaginian, R. M., Richardson, J. M., Pardo, S. A., Stuhr, A., & Freckmann, G. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221080916 · Cited by 10
Harris, S. B., Idzik, S. R., Boasso, A., Neunie, S., Noble, A., Such, H. E., & Van, J. T. (2022) · JMIR Medical Education · doi:10.2196/40520 · Cited by 12
Deng, Y., Polley, E. C., Wallach, J. D., Herrin, J. S., Ross, J. S., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000419 · Cited by 10
Pieber, T. R., Aronson, R., Christiansen, M. P., Bode, B., Junaidi, K., & Conoscenti, V. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14699 · Cited by 8
Treatment of bone fragility in patients with diabetes: antiresorptive versus anabolic?
Shah, M., Appuswamy, A. V., Rao, S. D., & Dhaliwal, R. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000645 · Cited by 10
Yu, G., Ma, H., Lv, W., Zhou, P., & Liu, C. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13662 · Cited by 10
Okoro, F. O., & Markus, V. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108954 · Cited by 10
Zhang, Y., Liu, J., Huang, W., Zhang, Y., Guo, X., Cao, H., Niu, X., Zhang, W., Li, Z., & Sun, W. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.113045 · Cited by 9
Haluzík, M., Cypryk, K., Alvarez, A., Lauand, F., Bakıner, O., & Lim, S. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16276 · Cited by 8
Gómez, A., Henao, D. C., Taboada, L. B., Fuentes, O., Lucero, O. J. M., Sanko, A. A., Ma, R., Múñoz, Ó., Rondón, M., García-Jaramillo, M., et al. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s288526 · Cited by 10
Punnose, J., Malhotra, R. K., Sukhija, K., Rijhwani, R. M., Sharma, A., Choudhary, N., Vij, P., & Joseph, R. (2022) · Sultan Qaboos University medical journal · doi:10.18295/squmj.3.2022.022 · Cited by 10
Exercise and Self-Management in Adults with Type 1 Diabetes
McCarthy, M. M., Ilkowitz, J. T., Zheng, Y., & Dickson, V. V. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01707-3 · Cited by 13
The Association Between Cost-Related Non-Adherence Behaviors and Diabetes Outcomes
Chiang, Y.-C., Ni, W., Zhang, G., Shi, X., & Patel, M. R. (2023) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2022.220272r2 · Cited by 9
Raj, S. C., Mishra, A. K., Mohanty, D., Katti, N., Pattnaik, S., Patra, L., & Pattanaik, A. (2023) · Clinical Advances in Periodontics · doi:10.1002/cap.10262 · Cited by 9
Charu, V., Liang, J. W., Chertow, G. M., Li, J., Montez‐Rath, M. E., Geldsetzer, P., de Boer, I. H., Tian, L., & Tamura, M. K. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000272 · Cited by 10
“8 – 12 Unfortunately, clear criteria for how to individ-ualize glycemic targets are lacking.”
BackgroundMorissette, A., & Mulvihill, E. E. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13065 · Cited by 8
Tokutsu, A., Okada, Y., Torimoto, K., & Tanaka, Y. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00663-2 · Cited by 8
Weekly Insulin Becoming a Reality
Skyler, J. S. (2021) · Diabetes Care · doi:10.2337/dci21-0011 · Cited by 8
Kawaguchi, Y., Miyamoto, S., Hajika, Y., Ashida, N., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13677 · Cited by 8
Sudheer, P., Vibha, D., & Misra, S. (2022) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_566_21 · Cited by 8
Kwan, A. Y. M., Gerstein, H. C., Basile, J., Xavier, D., Maldonado, J. M., Raha, S., & Кониг, М. (2022) · Diabetes Care · doi:10.2337/dc21-1160 · Cited by 9
Association of Dietary and Plasma Magnesium with Glycaemic Markers in a Chinese Population
Xu, M., Cai, J., Mo, X., Liu, Q., Zhang, J., Wei, Y., Liu, S., Lin, Y., Huang, S., Mo, C., et al. (2022) · Biological Trace Element Research · doi:10.1007/s12011-022-03172-z · Cited by 8
Li-jing, W., Ke, S., Wang, L., Lishan, H., Liqin, Q., Zhan, Z., Kejun, W., Mengjun, Z., Xiaoying, L., Xiaohong, L., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.843556 · Cited by 10
Khan, J., & Shaw, S. (2023) · The Aging Male · doi:10.1080/13685538.2023.2208658 · Cited by 9
“Parallel to the significant epidemiological burden of type-2 diabetes that India carries, diabetes control in India has also failed to maintain the global standards of mean HbA1c � 7% and almost half of the people with diabetes remain undiagnosed across India [53,54].”
BackgroundFeng, W., Chen, W., Jiang, S., Du, L., & Zhu, D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14392 · Cited by 9
Davidsen, L., Cichosz, S. L., Stæhr, P., Vestergaard, P., Drewes, A. M., Knop, F. K., Jensen, M. H., & Olesen, S. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16356 · Cited by 9
Bergenstal, R. M., Xu, Y., Dunn, T. C., Choudhary, P., & Ajjan, R. (2026) · Diabetologia · doi:10.1007/s00125-026-06739-w · Cited by 10
“The main goal is to determine whether uGMI reduces the biases across clinically relevant HbA 1c ranges compared with GMI, thereby supporting adoption of the uGMI in routine clinical practice [11].”
Hayek, A. A., Sobki, S. H., Alsaeed, A. H., Alzahrani, W. M., & Dawish, M. A. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01240-0 · Cited by 9
Risk Factors for Hypoglycemia During Treatment of Hyperglycemic Crises
Ross, R. C., Vadakkel, N., Westmoreland, K., Hendrickson, A. L., Balazh, J. R., Telford, E. D., & Franck, A. J. (2022) · Diabetes Spectrum · doi:10.2337/ds21-0094 · Cited by 8
Utilizing the New Glucometrics: A Practical Guide to Ambulatory Glucose Profile Interpretation
Doupis, J., & Horton, E. S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.20 · Cited by 14
“32 If 4% of sensor glucose readings are below 70 mg/dL, the patient is on target, and the consultation can move on.”
Backgroundde Souza, A. B. C., Corrêa‐Giannella, M. L., Gomes, M. B., Negrato, C. A., & Nery, M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000523 · Cited by 11
Wu, S.-Y., Wu, C., Lin, L., Chen, Y., Huang, H.-Y., Lai, Y., & Lee, S. (2023) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2023.06.001 · Cited by 9
Lord, J., Reid, K. M., DuClos, C., Mai, A., & Odoi, A. (2023) · BMC Public Health · doi:10.1186/s12889-023-17288-x · Cited by 11
Rodríguez-Sarmiento, D. L., Jutinico, A. L., & Vargas, F. M. L. (2024) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2024.106166 · Cited by 7
Wen, M., Salihu, E. Y., Yang, C., Maurer, M. A., & Shiyanbola, O. O. (2024) · Pharmacy · doi:10.3390/pharmacy12030075 · Cited by 7
“Compared to non-Hispanic white adults, African American adults are 60% more likely to be diagnosed with diabetes and are more likely to experience diabetes-related kidney disease and amputations compared to white adults, leading to increased hospitalizations and death [2–4].”
BackgroundQiu, W., Cai, A., Zhiqiang, N., Wang, J.-B., Ou, Y., & Feng, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15653 · Cited by 9
Propper‐Lewinsohn, T., Shalitin, S., Gillon‐Keren, M., Yackobovitch‐Gavan, M., Liberman, A., Phillip, M., & Elran‐Barak, R. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0267 · Cited by 8
“26 Elevated BMI Z score, HbA1c, diabetes distress, diabetes-speci fi c disinhibited eating, and lower socioeconomic status were associated with DEB.”
Tang, X., Li, Q., Han, Y., Wang, X., Song, Y., Zhang, Z., Jingjing, X., Liu, Z., Chen, Y., Zhang, Y.-Z., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39748 · Cited by 7
Sugar and stops in drivers with insulin-dependent type 1 diabetes
Barnwal, A., Chakraborty, P., Sharma, A., Riera-Garcia, L., Ozcan, K., Davami, S., Sarkar, S., Rizzo, M., & Merickel, J. (2022) · Accident Analysis & Prevention · doi:10.1016/j.aap.2022.106692 · Cited by 10
Fakhroleslam, M., & Boozarjomehry, R. B. (2021) · Asia-Pacific Journal of Chemical Engineering · doi:10.1002/apj.2651 · Cited by 7
Sauder, K. A., Stafford, J. M., Ehrlich, S. R., Lawrence, J. M., Liese, A. D., Marcovina, S. M., Mottl, A. K., Pihoker, C., Saydah, S., SHAH, A. S., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2983 · Cited by 7
Frías, J. P., Bonora, E., Cox, D. A., Bethel, M. A., Kwan, A. Y. M., Raha, S., & Malik, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14533 · Cited by 8
Kim, J. A., Park, M., Song, E., Roh, E., Park, S. Y., Lee, D. Y., Kim, J., Yu, J. H., Seo, J. A., Choi, K. M., et al. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0293 · Cited by 7
Park, J., Park, N., Han, S., Lee, Y., Kim, G., Jin, S., Lee, W. J., & Kim, J. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0299 · Cited by 8
Abubaker, S., Albasseet, A., Elabd, K., Alandijani, A. A., Alendijani, Y., & Alkhenizan, A. H. (2022) · Cureus · doi:10.7759/cureus.25919 · Cited by 7
Candido, R., Modugno, M., Larosa, M., Rossi, M. C., Nicolucci, A., Gabellieri, E., & the ENSURE Study Group (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01328-7 · Cited by 8
Burnette, S., Poehlein, E., Lee, H., Force, J. M., Westbrook, K. E., & Moore, H. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06798-8 · Cited by 8
Abusnana, S., Alawadi, F., Aly, H., Bashier, A. M., Dhanwal, D. K., Halasa, T., Jallo, M. K. I., Medina, J., & Singhal, S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110183 · Cited by 8
Burslem, R., & Parker, A. (2021) · Nutrition in Clinical Practice · doi:10.1002/ncp.10728 · Cited by 6
Rethy, L. B., Vu, T.-H. T., Shah, N. S., Carnethon, M. R., Lagu, T., Huffman, M. D., Yancy, C. W., Lloyd‐Jones, D. M., & Khan, S. S. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009229 · Cited by 6
Soriano, E. C., Lenhard, M. J., Gonzalez, J. S., Tennen, H. A., Otto, A. K., Perndorfer, C., Shen, B., Siegel, S. D., & Laurenceau, J. (2022) · Psychosomatic Medicine · doi:10.1097/psy.0000000000001106 · Cited by 8
Ali, A. M., Cobran, E. K., & Young, H. N. (2022) · Pharmacy · doi:10.3390/pharmacy10040079 · Cited by 10
Tirzepatide for Patients With Type 2 Diabetes
Chipkin, S. R. (2022) · JAMA · doi:10.1001/jama.2021.25016 · Cited by 8
Simulation Platform Development for Diabetes and Technology Self-Management
Faulds, E. R., Rayo, M. F., Lewis, C. J., Noble, C. W., Gifford, R. C., Happ, M. B., Joyce, L., & Dungan, K. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211029303 · Cited by 8
End-to-end offline reinforcement learning for glycemia control
Beolet, T., Adenis, A., Huneker, E., & Louis, M. (2024) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2024.102920 · Cited by 13
Alhazmy, R. S., Khalil, A. H., & Almutary, H. H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305845 · Cited by 6
“According to the Saudi Diabetes Clinical Practice Guidelines, the normal HbA1c level is 4%–5.6% [18].”
MethodInfluentialPredicting hypoglycemia in elderly inpatients with type 2 diabetes: the ADOCHBIU model
Zhang, R.-T., Liu, Y., Sun, C., Wu, Q.-Y., Guo, H., Wang, G., Lin, K., Wang, J., & Bai, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1366184 · Cited by 9
Wu, K., Qi, X., Li, A., Dong, H., Wang, X., & Ji, M. (2025) · Nursing Reports · doi:10.3390/nursrep15030090 · Cited by 11
“Glycated hemoglobin (HbA1c) within the last three months was used to reflect individuals’ glycemic control, and HbA1c 7% was interpreted as optimal [42].”
InfluentialTsopmejio, I. S. N., Tang, S., Gao, X.-F., Liu, Z., Li, X., Qi, M.-H., Zhu, H., Wang, Z., & Li, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115378 · Cited by 7
He, R., Sun, H., Liu, H., & Li, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1648823 · Cited by 11
Ceriello, A., Rizvi, A. A., & Rizzo, M. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01942-0 · Cited by 7
Schönenberger, K. A., Ferreira, A., Stebler, C., Prendin, F., Gawinecka, J., Nakas, C. T., Mühlebach, S., Stanga, Z. G., Facchinetti, A., Herzig, D., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15175 · Cited by 9
Aziz, F., Sternad, C., Sourij, C., Knoll, L., Kojzar, H., Schranz, A., Bürger, A., Sourij, H., & Aberer, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15409 · Cited by 6
Aljuhani, R. T., Adas, M., Alnaami, R., Alshehri, R., Alqarni, R., NoorSaed, S., & Al-Agha, A. E. (2024) · Cureus · doi:10.7759/cureus.51496 · Cited by 9
“The constant feedback from rtCGM can aid in well-informed management decisions that go beyond what is achievable with SMBG alone [15], potentially enhancing diabetes care for children and adolescents with T1D.”
BackgroundStantonyonge, N., Martínez‐Horta, S., Sampedro, F., Sánchez‐Saudinós, M. B., & Chico, A. I. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108898 · Cited by 5
2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes
Chiang, C., Ueng, K., Chao, T., Lin, T., Wu, Y., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2021) · JACC Asia · doi:10.1016/j.jacasi.2021.08.003 · Cited by 7
Abildgaard, A. M., Knudsen, C. S., Bjerg, L. N., Lund, S. A., & Støy, J. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0720 · Cited by 10
Cherni, I., Nouir, R., Ghalila, H., Somai, M., Daoued, F., Aydi, Z., Hamzaoui, S., BOUSSEMA, F., & Jaidane, N.-E. (2022) · Applied Optics · doi:10.1364/ao.454245 · Cited by 6
Fantahun, B., & Leulseged, T. W. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2022-0144 · Cited by 8
Franek, E., Gerstein, H. C., Riddle, M. C., Nicolay, C., Hickey, A., Botros, F. T., & Loo, L. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14760 · Cited by 9
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S73-S84
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4236126199
- Cited by
- 847
- References
- 118
- Citations by year
- 2026: 43 · 2025: 80 · 2024: 115 · 2023: 156 · 2022: 265 · 2021: 187 · 2020: 1
- FWCI
- 23.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic targets, diabetes management, clinical guidelines, quality of care, level of evidence, treatment goals
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.